Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open-label, phase III trial in up to 2000 patients with known or suspected benign or malignant tumors which are known or suspected to be 18F-fluorocholine-avid. Patients will receive regular standard clinical care. The only study-specific procedure will be the administration of 18F-fluorocholine followed by a PET/CT scan. Diagnostic accuracy of 18F-fluorocholine PET/CT will be captured versus a composite clinical, radiological and histopathological standard of truth at follow-up.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04150458
Study type Interventional
Source Sir Mortimer B. Davis - Jewish General Hospital
Contact
Status Enrolling by invitation
Phase Phase 3
Start date November 30, 2022
Completion date July 2030